A three-year-old Kendall Square biotech startup that received a $70 million investment from Vertex Pharmaceuticals in May is joining Watertown’s expanding life science corridor.

Kymera Therapeutics leased nearly 35,000 square feet in Building A, the first office and lab component of the Arsenal Yards mixed-use project. Under terms of the four-year research partnership, Vertex received an equity position and Kymera will be eligible to receive over $1 billion in payments based upon successful commercialization of up to six programs, the companies said at the time.

Headquartered at 300 Technology Square in Cambridge, Kymera Therapeutics was co-founded and incubated in 2016 by Cambridge-based Atlas Venture, which led a $30 million round of series A funding.

Kymera’s lease runs for 10 years, according to a Middlesex County Registry of Deeds filing. The company researches drugs that help the body’s protein recycling system fight disease.

SQZ Biotech of Watertown was the first life science firm to commit to Arsenal Yards in January, leasing 63,477 square feet in a relocation from 134 Coolidge Ave.

Via brokerage Cushman & Wakefield, Arsenal Yards now is marketing 168,000 square feet of lab-ready space in building G which is scheduled to break ground in early 2020.